Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.

A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection.

Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals with Co-Occurring Tobacco Dependence and Serious Mental Illness.

Commentary on Winhusen et al. (2019): Substance use disorders, chronic diseases, and electronic health records-a paradigm for screening and intervention.

Clinical epidemiology of substance use disorders: Understanding patterns, sharing knowledge, planning interventions.

Prevalence and patterns of opioid misuse and opioid use disorder among primary care patients who use tobacco.

Opioid use disorder deaths and the effects of medication therapy.

The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial.

Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone.

Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients.

Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.

Transition to Extended-release Naltrexone: Heroin Versus Prescription Opioid Users

Outpatient Transition to Extended-release Naltrexone in Patients With Opioid-use Disorder

Substance use disorders and medical comorbidities among high-need, high-risk patients with diabetes.

Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.

Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States.

The opioid overdose epidemic: opportunities for pharmacists.

Family substance use screening: less to hide, more to gain.

Primary care for opioid use disorder.

Pharmacological and Integrated Treatments in Older Adults with Substance Use Disorders

Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

Cannabis use disorders are comparatively prevalent among nonwhite racial/ethnic groups and adolescents: a national study.

Substance Use Outcomes of an Integrated HIV-Substance Use Treatment Model Implemented by Social Workers and HIV Medical Providers

Comorbid substance use disorders with other Axis I and II mental disorders among treatment-seeking Asian Americans, Native Hawaiians/Pacific Islanders, and mixed-race people.

Smoking and opioid detoxification: behavioral changes and response to treatment.

The burden of caring: drug users & their families.

Evaluating brief screeners to discriminate between drug use disorders in a sample of treatment-seeking adults.

Alcohol and drug use disorders among adults in emergency department settings in the United States.

Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.

The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.

An integrated alcohol abuse and medical treatment model for patients with hepatitis C.

Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Once-monthly extended-release naltrexone injections improve opioid abstinence over 24 weeks compared with placebo.

Pharmacological enhancement of naltrexone treatment for opioid dependence: a review.

Problem drinking and low-dose naltrexone-assisted opioid detoxification.

Differences in onset and abuse/dependence episodes between prescription opioids and heroin: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Reduced cannabis use after low-dose naltrexone addition to opioid detoxification.

Agonist-antagonist combinations in opioid dependence: a translational approach.

Opioid use affects antioxidant activity and purine metabolism: preliminary results.

Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study.

History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia.

The high prevalence of substance use disorders among recent MDMA users compared with other drug users: Implications for intervention.

Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.

Early outcomes following low dose naltrexone enhancement of opioid detoxification.

Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial.

Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.

A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome.

History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.

Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence.

Hallucinogen use disorders among adult users of MDMA and other hallucinogens.

Prescription pain reliever abuse and dependence among adolescents: a nationally representative study.

Reply to Dr Ng's comments on "A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation with An Extended Release Formulation of Methylphenidate in Outpatients with Treatment-Resistant Depression" [11]

An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features.

Polypharmacy in pregnant women with major psychiatric illness: a pilot study.

Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.

Long-acting injectable naltrexone for the treatment of alcohol dependence.

Trends in nonheroin opioid abuse admissions: 1992-2004.

Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal.

Recent advances in poststroke depression.

Medical comorbidity and alcohol dependence.

A randomized, controlled, trial of controlled release paroxetine in fibromyalgia.

Sodium oxybate for the treatment of fibromyalgia: A double-blind, placebo-controlled trial

Bupropion reinstates cocaine seeking behavior in rats

A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.

Polymorphism in the serotonin transporter gene and moderators of prolactin response to meta-chlorophenylpiperazine in African-American cocaine abusers and controls.

Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence.

A randomized, double-blind, placebo-controlled, flexible-dose, trial of augmentation with OROS methylphenidate in Treatment Resistant Depression

Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients.

Elevated mu-opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal signs after chronic low dose naltrexone in opiate-dependent rats.

Changes in tobacco smoking following treatment for cocaine dependence.

Antagonist treatment of opioid withdrawal translational low dose approach.

An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression.

A functional prodynorphin promoter polymorphism and opioid dependence.

Polymorphism in the serotonin transporter gene and response to treatment in African American cocaine and alcohol-abusing individuals.

Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence.

Medical symptoms associated with tobacco smoking with and without marijuana abuse among crack cocaine-dependent patients.

The distribution of cocaine in mice differs by age and strain.

Relationship of serum prolactin with severity of drug use and treatment outcome in cocaine dependence.

Chronic very low dose naltrexone administration attenuates opioid withdrawal expression.

Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine-dependent individuals and healthy volunteers.

Comparison of pretreatment characteristics and treatment outcomes for alcohol-, cocaine-, and multisubstance-dependent patients.

Pre-treatment measures of impulsivity, aggression and sensation seeking are associated with treatment outcome for African-American cocaine-dependent patients.

Relationship of Aggression, Sensation Seeking, and Impulsivity, with Severity of Cocaine Use

High- and low-structure treatments for substance dependence: role of learned helplessness.

Continuing care versus revolving door following opiate detoxification

Use of very low-dose naltrexone during opiate detoxification.

Very low antagonist dosing in opiate detoxification

Psychological discomfort and mental illness in patients with AIDS: implications for home care.

Emergency therapeutical approach simulating ultrarapid opioid detoxification in methadone withdrawal precipitated by erroneous administration of naltrexone.

Serendipitous rapid detoxification from opiates: the importance of time-dependent processes.

Adjuvant trazodone in the treatment of alcoholism: an open study.

Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics.

Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine.

Low-dose buprenorphine detoxification in long term methadone addicts

Sources of differentiation of cocaine withdrawal symptomatology

Prediction in drug abuse: cocaine interactions with alcohol and buprenorphine.

Prediction in drug abuse: Cocaine interactions with alcohol and buprenorphine

Psychological status, life and social conditions: A study in a population of institutionalized elderly people

Serotoninergic hypothesis on the drug mechanism of cocaine

Benzodiazepine use and dependency risk in geriatric inpatients

[Benzodiazepines consumption and risk of dependence in institutionalized geriatric patients].

Zipeprol is a newly abused antitussive with an opioid spectrum and hallucinogenic effects.

Patterns of cocaine abuse and indications for treatment

Serotoninergic hypothesis on the drug mechanism of cocaine

Benzodiazepine use and dependency risk in geriatric inpatients

Clinical reports on recent abuse of an antitussive.

Lefetamine: new abuse of an old drug--clinical evaluation of opioid activity.

Lephetamine abuse and dependence: clinical effects and withdrawal syndrome.